top of page
Speaker backround.png


Our program features researchers from the nordic countries as well as international actors. Here are the speakers you will meet:

Hamilton Morris

Journalist, documentarian and pharmacological researcher

Hamilton is an American journalist, documentarian, and scientific researcher. He is the creator and director of the television series Hamilton's Pharmacopeia, in which he investigated the chemistry, history, and cultural impact of various psychoactive drugs.


Dr Ben Sessa

Chief Medical Officer at AWAKN Life Sciences

Dr Ben Sessa is Chief Medical Officer at Awakn Life Sciences, a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. As a consultant child and adolescent psychiatrist, Dr Sessa  has worked with young people and adults in the field of  addictions and trauma-related psychiatry for over 20 years.

Over the last 15 years, Dr Sessa has been part of many  ground-breaking scientific and clinical studies administering psychedelic compounds to augment psychotherapy. He has recently completed research with Imperial College London exploring the world’s first MDMA-assisted therapy  trial for the treatment of Alcohol Use Disorder and continues to carry out research in this area. Dr Sessa is also an  experienced medical cannabis prescriber. Dr Sessa is widely published in the academic and popular press in respect  of the field of medical psychedelics. He has written several academic books, notably The Psychedelic Renaissance (2012/2017). Dr Sessa is a trained MDMA and psilocybin therapist and has delivered keynote talks at international conferences in the psychedelic community for 15+ years.

Dr Danielle Schlosser

Senior Vice President of Clinical Innovation at COMPASS Pathways

Danielle Schlosser is the Senior Vice President of Clinical Innovation at COMPASS Pathways, a mental health company dedicated to accelerating access to evidence-based innovation in mental health. She leads the function responsible for their clinical care model development, therapy optimization research, and therapist training. She is a clinical psychologist with over 15 years as a digital health innovator, clinical scientist, and human-centered thinker. She remains on the faculty at the University of California, San Francisco where she used to lead a translational neuroscience lab. The lab developed digital therapeutics for individuals with serious mental illness. She serves as Board Chair of OneFifteen, Co-Chair of the World Economic Forum Global Futures Council on Mental Health and Technology; and remains a faculty mentor for several fellowship programs at UCSF.


Dr David Erritzoe

Psychiatrist, London Imperial College - Centre for Psychedelic Research

David conducts psychopharmacological research, using brain-imaging techniques such as PET and MRI. Currently, he runs lab-based multi-modal brain imaging studies [often using pharmacological challenges] focusing on serotonin/dopamine/opiate neurotransmission as well as larger-scale prospective, naturalistic studies with online assessments and/or field-based data collection. Specifically, in the Centre for Psychedelic Research, studies are undertaken together with Prof Nutt and Dr Carhart-Harris, investigating brain mechanisms and therapeutic potential of MDMA, ketamine and classic psychedelics.

Professor Rasmus W. Licht

Professor of psychiatry at University of Aalborg and research director at Psykiatrien - Aalborg University Hospital

Rasmus W. Licht is chief psychiatrist at Aarhus University in Denmark where he does research on psilocybin for treatment-resistant depression.


Dr Atila Szabo PhD

Immunologist and Research Fellow at the University of Oslo

Attila's current research projects focus on psychoneuroimmunology, biological psychiatry, and brain-immune interactions in neuropsychiatric disorders. He has also been conducting various research projects on serotonergic psychedelics and their modulating role on inflammation, immune responses and related molecular pathways. Attila is the Editor-in-Chief at the Journal of Psychedelic Studies, and Associate Editor at Frontiers in Psychiatry.

Professor Willy Pedersen

Professor of sociology at the University of Oslo 

Willy has worked on issues related to deviance, marginalization and culture with empirical research projects focusing on adolescence, alcohol and drugs, crime and sexuality. He has published a large number of articles in international peer-reviewed journals as well as a large number of books and is a regular writer for Norwegian newspapers, including Aftenposten, Dagbladet and Morgenbladet. In recent years Willy has published several articles on recreational use of psychedelics in Norway. 

tor morten.png

Dr Tor Morten Kvam

Psychiatrist at PsykForsk, Sykehuset Østfold

Tor-Morten is currently a therapist in the European phase II trial investigating MDMA-assisted therapy for post-traumatic disorder, and his PhD will focus on MDMA-assisted therapy for major depressive disorder.

Dr Dea Siggaard Stenbæk PhD

Psychologist and neuroscientist at the Danish Center for Psychedelic Research

Dea Siggaard Stenbæk is a licensed clinical psychologist with a PhD in neuroscience. She is Associate Professor in Consciousness Studies at University of Copenhagen and Rigshospitalet, and study the effects of ‘extra-pharmacological’ factors, e.g., use of music and psychological setting, on the psychological and clinical effects of psilocybin. Internationally, she is closely affiliated with the Centre for Psychedelic Research at Imperial College, London.

Group 271.png

Dr. Michael Winkelman, M.P.H. PhD

University of California-Irvine

Michael James Winkelman is retired from the School of Human Evolution and Social Change at Arizona State University. Winkelman engages cross-cultural and interdisciplinary research on shamanism and its biological bases in Shamans, Priests and Witches and Shamanism: A Biopsychosocial Paradigm of Consciousness and Healing (2010).  He addressed the therapeutic applications of psychedelics in his co-edited Psychedelic Medicine (2007) and Advances in Psychedelic Medicine (2019). Winkelman examined the intersection of psychedelics and the evolutionary origins of religion in his co-authored Supernatural as Natural (2008) and a Journal of Psychedelic Studies Special Issue on Psychedelics in History and World Religion (2019). He has also explored the applications of shamanism and psychedelics to treatment of addiction.

Dr Mathias Ebbesen Jensen

PhD candidate at the Psychiatric Centre Copenhagen, Rigshospitalet

Mathias investigates mechanisms and efficacy of novel pharmacotherapies for treatment of alcohol use disorder. He is the initiator of a trial of psilocybin therapy for alcohol use disorder.  

Group 280.png
Group 282.png

Dr. Bolette Daniels Beck PhD

Assistant professor at Aalborg University, Denmark. 

Bolette Daniels Beck, PhD, assistant professor, Aalborg University, Denmark. Guided Imagery and Music therapist and trainer. Attached to The Music therapy research clinic at Aalborg Psychiatric Hospital, and to Rigshospitalet, NRU, Copenhagen. Published on effects of and processes in receptive music therapy with stress and PTSD patients.

Amy Emerson

Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC)

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Group 281.png

Johan Eriksson 

Clinical psychologist

Johan Eriksson is a licensed psychologist running a private practice in Stockholm working with a target group of clients in need of psychedelic harm reduction and integration. He is currently part of the instructor team at Fluence in New York, where he teaches online classes on psychedelic integration and mentors students in their certificate programs.

At present he is also employed as a therapist in the ongoing clinical trial PSIPET at Karolinska Institute, where psilocybin-assisted psychotherapy is being tested for depression. In 2016 he co-founded the Swedish Network for Psychedelic Science where he remained a board member until 2021.

Last year he co-founded the psychedelic science start-up Nysnö AB and is head-facilitator running legal psilocybin retreats in the Netherlands.

Dr Andreas Wahl Blomkvist

M.D., researcher and author

Andreas Wahl Blomkvist is a M.D., researcher and author. He works as a senior consultant at the department of addiction medicine at University Hospital of North Norway. He is the author of the book "Ulovlig Medisin" (Illicit Medicine) and board member for the Norwegian Association for Psychedelic Science. He is head of the advisory board for the Association for Safer Drug Policies. For his contribution on assisted dying, he was awarded Christian Sandsdalenpris in 2019. 

Group 294.png
Group 296.png

Ivar Goksøyr

Clinical psychologist, specialist

Ivar W. Goksøyr is a psychologist specialized within Intensive short-term dynamic psychotherapy (ISTDP). Goksøyr is affiliated with the unit "Psykforsk - Innovative Treatment Research", at the Hospital in Østfold. He works here to prepare participation in international treatment studies with psychedelic drugs. He has received training in MDMA-assisted psychotherapy by the Multidisciplinary Association for Psychedelic Studies (MAPS) and treatment with Psilocybin.

Dr Eva Henje

Associate Professor at Umeå University

Eva Henje is associate professor at the department of clinical science at Umeå University and a senior specialist in child and adolescent psychiatry. Her research is based in contemplative neuroscience, systemic biomarkers and traumatherapy and aims to develop more effective treatment for trauma and stress-related disorders such as depression, anxiety, insomnia and emotion dysregulation in youth and young adults. She is co-investigator in a randomized controlled trial testing psilocybin vs placebo for depression at the Karolinska Institutet and a learning mentor in the psychedelic practitioner training offered by the Synthesis Institute in the Netherlands

Group 304.png
Group 305.png

Dr Malin Vedøy Uthaug PhD

PhD, researcher

Dr Malin Vedøy Uthaug has a background in psychology and her PhD at Maastricht University she researched the effects of naturalistically ingested ayahuasca and 5-MeO-DMT. After this she went on to do her post-doc at The Centre for Psychedelic Research at Imperial College London. Here she managed studies on the effects of both 5-MeO-DMT and Holotropic Breathwork. Dr Uthaug is currently employed as a postdoctoral researcher at Swinburne University of Technology in Melbourne, Australia. Here she is leading a clinical hypothesis-generating research study aimed to explore the holistic effects of intramuscularly ingested 5-MeO-DMT. 

Professor Celia Morgan

Head of ketamine assisted psychotherapy for addiction at Awakn Life Sciences

Prof. Celia Morgan is Head of Ketamine-Assisted Psychotherapy for alcohol use disorder practice at Awakn Life Sciences, a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Through behavioural, neuroimaging studies and clinical trials, Prof. Morgan has investigated the effects of ketamine and MDMA in combination with psychological therapies aimed at the treatment of addiction. She carried out the ground-breaking Ketamine for reduction of Alcoholic Relapse (KARE) trial – a recent randomised controlled trial exploring combined use of psychological therapy and a low dose of ketamine as a possible treatment for alcoholism – the first of its kind.

Group 308.png
Group 306.png

Otto Simonsson Post. doc

Karolinska Institutet

Otto Simonsson is a postdoctoral researcher at Karolinska Institutet, where he conducts experimental and epidemiological research on psychedelics and meditation.

Professor Ole Martin Moen

Philosopher and professor at OsloMet

Ole Martin Moen is a Norwegian philosopher who works primarily with applied ethics and value theory. He is Professor of Ethics at Oslo Metropolitan University and Researcher in Philosophy and Principal Investigator for the 5-year research project "What should not be bought and sold?" at the University of Oslo, funded by the Research Council of Norway. Moen's research also involves topics regarding drugs and he has published several articles in leading international journals such as Journal of Medical Ethics, Bioethics, Neuroethics and Philosophical Studies.

Group 309.png
Group 307.png

Måns Bergkvist

President of the Swedish Network for Psychedelic Science.

Måns (B.Sc. in law) is the president of the Swedish Network for Psychedelic Science. He’s interested in the history of psychedelic science, with a particular focus on the paradigm collisions within the medical field during the 1960s.

Måns is currently co-authoring a meta-analysis of all studies conducted on the effects of psilocybin published between 1958 and 1976.

Kristoffer Andersen 

Clinical psychologist at Awakn Clinics, Oslo

Kristoffer Andersen is a Norwegian psychologist with experience in long-term individual and group psychodynamic psychotherapy. Since 2019 Kristoffer has been providing adherence rating for MAPS in the MDMA-assisted psychotherapy for PTSD clinical trials. For the last year he has been working at Awakn clinics (previously known as Axonklinikken), providing ketamin-assisted psychotherapy for patients with moderate to severe depression. Previously associated with London Imperial College where he was awarded honorary research associate at Centre for psychedelic research. Currently leading a research project with the aim of providing psychometrically valid and reliable rating scales for use in future psychedelic research trials in Norway. Kristoffer is board member of the Norwegian Association of Psychedelic Science. 

Group 297.png

Dr. Henrik Børsting Jacobsen

Senior Researcher, University of Oslo, Department of Psychology.
Ph.D. in stress and behavioral medicine, clinical specialist in health psychology.

Henrik Børsting Jacobsen is a psychologist and senior researcher at the Oslo University Hospital. In his doctoral dissertation, he looked at the connection between stress and chronic pain and ailments. After this, he has continued to research various aspects related to chronic pain.

Dr. Ingmar Clausen

Psychiatrist and head of DPS North Østfold

Dr. Ingmar Clausen is the head of DPS North Østfold at Østfold Hospital, where he is responsible for the introduction of ketamine treatment and conducting clinical studies with psychedelic drugs.


Filip Bromberg 

Psychologist & research facilitator

Filip Bromberg is a clinical psychologist in Stockholm, co-founder of the Swedish Network of Psychedelic Science, and chairman of Osmond Foundation.

Want to present your work?

Send us an e-mail at


Willy Pedersen
Attila Szabo
Rasmus W. Licht
David Erritzoe
Ben Sessa
Tor Morten Kvam
Amy Emerson
Eva Henje
Malin Uthaug
Celia Morgan
Otto Simonsson
Ole Martin Moen
Måns Bergkvist
bottom of page